Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: About CDC.gov.

New CDC Data for TB in the U.S. – Key Graphics

On this Page

From this page, you may download several different options of the full infographic highlighting findings from CDC’s new cost analysis for the treatment of drug resistant TB (downloadable PDF and high-resolution version, as well as embeddable images). Individual components of the infographic are also available. Additionally, graphics highlighting major findings from CDC’s analysis of 2013 national surveillance data are available for download.

These images are in the public domain and are thus free of any copyright restrictions. As a matter of courtesy, we request that the content provider be credited and notified of any public or private usage of an image.

Please note that these resources are for reporters. If you are a member of the general public and seek additional information about TB, please visit http://www.cdc.gov/tb/. If you have additional questions, please call 1(800) CDC INFO or email cdcinfo@cdc.gov.

Infographic: Costly Burden of Drug-Resistant TB

The Costly Burden of Drug-Resistant TB in the United States
View High Resolution Version
Multidrug-resistant (MDR) tuberculosis is a major health threat globally. Nearly half a million MDR TB cases are estimated to occur worldwide annually, including cases that are extensively drug-resistant (XDR).

This infographic highlights that while MDR and XDR TB are relatively rare in the U.S., their treatment comes at a terrible price – it is very expensive, takes a long time to treat, disrupts lives, and has potentially life-threatening side effects.

Embeddable Images: Costly Burden of Drug-Resistant TB

Infographic Components: Costly Burden of Drug-Resistant TB

The Outsized Financial Toll of MDR and XDR TB

View High Resolution VersionThe average cost of treating each TB case increases with greater resistance. Average direct cost ranges from $17,000 to treat drug-susceptible TB to $430,000 to treat the most drug-resistant form of the disease (XDR TB). When including productivity losses experienced by patients while undergoing treatment, costs are even higher.

A Major Human Cost

View High Resolution VersionIn addition to the economic toll, treatment for drug-resistant TB comes at a major cost to patients’ quality-of-life. Of those treated for drug-resistant TB 9% died during treatment; 27% stopped working; 73% were hospitalized; and 37% required home isolation.

Graphics: Key 2013 National TB Surveillance Data

Reported TB Cases in the United States, 1982-2013

View High Resolution VersionThe resurgence of TB in the mid-1980s was marked by several years of increasing case counts until its peak in 1992. Case counts began decreasing again in 1993, and 2013 marks the 21st year of decline in the total number of TB cases reported in the United States since the peak of the resurgence.

TB Rates by Race/Ethnicity, 2013

View High Resolution VersionAlthough TB rates declined among all racial/ethnic groups, TB rates among racial/ethnic minorities are much higher than those of whites. Rates for Asians (18.7/100,000), blacks (5.3), and Hispanics (5.0) were 26, seven, and seven times higher than among whites (0.7), respectively.

Proportion of TB Cases by National Origin, 2013

View High Resolution VersionDespite declines in the rates of TB among both foreign- and U.S.-born individuals, the TB rate among foreign-born persons was 13 times higher than among U.S.-born persons.